vs
Emergent BioSolutions Inc.（EBS）とRepay Holdings Corp（RPAY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Emergent BioSolutions Inc.の直近四半期売上が大きい（$148.7M vs $78.6M、Repay Holdings Corpの約1.9倍）。Emergent BioSolutions Inc.の純利益率が高く（-36.7% vs -178.3%、差は141.6%）。Repay Holdings Corpの前年同期比売上増加率が高い（0.4% vs -23.6%）。Emergent BioSolutions Inc.の直近四半期フリーキャッシュフローが多い（$73.8M vs $23.2M）。過去8四半期でRepay Holdings Corpの売上複合成長率が高い（-1.3% vs -29.6%）
Emergent BioSolutionsはアメリカ合衆国メリーランド州ゲイザーズバーグに本社を置く多国籍専門生物製薬企業です。感染症やオピオイド過剰摂取に対応するワクチンと抗体治療薬の開発を主力事業とし、生物防衛分野向けの医療機器も提供しています。
Repay Holdings Corpは北米を主要市場とする決済テクノロジー企業で、小売、医療、自動車サービス、電子商取引などの業種の企業向けに、クレジット・デビットカード決済処理、ACH送金、POSシステム連携を含む統合決済ソリューションを提供し、顧客の業務効率化を支援しています。
EBS vs RPAY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $148.7M | $78.6M |
| 純利益 | $-54.6M | $-140.1M |
| 粗利率 | 42.9% | 74.2% |
| 営業利益率 | -18.8% | -182.2% |
| 純利益率 | -36.7% | -178.3% |
| 売上前年比 | -23.6% | 0.4% |
| 純利益前年比 | -74.4% | -3304.1% |
| EPS（希薄化後） | $-0.95 | $-1.68 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $148.7M | $78.6M | ||
| Q3 25 | $231.1M | $77.7M | ||
| Q2 25 | $140.9M | $75.6M | ||
| Q1 25 | $222.2M | $77.3M | ||
| Q4 24 | $194.7M | $78.3M | ||
| Q3 24 | $293.8M | $79.1M | ||
| Q2 24 | $254.7M | $74.9M | ||
| Q1 24 | $300.4M | $80.7M |
| Q4 25 | $-54.6M | $-140.1M | ||
| Q3 25 | $51.2M | $-6.4M | ||
| Q2 25 | $-12.0M | $-102.3M | ||
| Q1 25 | $68.0M | $-7.9M | ||
| Q4 24 | $-31.3M | $-4.1M | ||
| Q3 24 | $114.8M | $3.2M | ||
| Q2 24 | $-283.1M | $-4.1M | ||
| Q1 24 | $9.0M | $-5.2M |
| Q4 25 | 42.9% | 74.2% | ||
| Q3 25 | 62.8% | 74.4% | ||
| Q2 25 | 52.5% | 75.7% | ||
| Q1 25 | 60.2% | 75.9% | ||
| Q4 24 | 39.4% | 76.3% | ||
| Q3 24 | 54.9% | 77.8% | ||
| Q2 24 | -18.8% | 78.2% | ||
| Q1 24 | 49.2% | 76.2% |
| Q4 25 | -18.8% | -182.2% | ||
| Q3 25 | 33.1% | -3.9% | ||
| Q2 25 | 1.1% | -138.7% | ||
| Q1 25 | 22.5% | -4.7% | ||
| Q4 24 | -4.9% | -1.5% | ||
| Q3 24 | 22.0% | -0.9% | ||
| Q2 24 | -79.9% | -4.6% | ||
| Q1 24 | 13.2% | -3.1% |
| Q4 25 | -36.7% | -178.3% | ||
| Q3 25 | 22.2% | -8.3% | ||
| Q2 25 | -8.5% | -135.2% | ||
| Q1 25 | 30.6% | -10.3% | ||
| Q4 24 | -16.1% | -5.3% | ||
| Q3 24 | 39.1% | 4.1% | ||
| Q2 24 | -111.2% | -5.4% | ||
| Q1 24 | 3.0% | -6.5% |
| Q4 25 | $-0.95 | $-1.68 | ||
| Q3 25 | $0.91 | $-0.08 | ||
| Q2 25 | $-0.22 | $-1.15 | ||
| Q1 25 | $1.19 | $-0.09 | ||
| Q4 24 | $-0.45 | $-0.04 | ||
| Q3 24 | $2.06 | $0.03 | ||
| Q2 24 | $-5.38 | $-0.04 | ||
| Q1 24 | $0.17 | $-0.06 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $205.4M | $115.7M |
| 総負債低いほど良い | $589.7M | $280.1M |
| 株主資本純資産 | $522.6M | $484.4M |
| 総資産 | $1.3B | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | 1.13× | 0.58× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $205.4M | $115.7M | ||
| Q3 25 | $245.5M | $95.7M | ||
| Q2 25 | $267.3M | $162.6M | ||
| Q1 25 | $149.1M | $165.5M | ||
| Q4 24 | $99.5M | $189.5M | ||
| Q3 24 | $149.9M | $168.7M | ||
| Q2 24 | $69.7M | $147.1M | ||
| Q1 24 | $78.5M | $128.3M |
| Q4 25 | $589.7M | $280.1M | ||
| Q3 25 | $693.1M | $279.5M | ||
| Q2 25 | $700.0M | $279.0M | ||
| Q1 25 | $700.0M | $497.6M | ||
| Q4 24 | $700.0M | $496.8M | ||
| Q3 24 | $700.8M | $496.2M | ||
| Q2 24 | $863.8M | $435.6M | ||
| Q1 24 | $909.2M | $434.9M |
| Q4 25 | $522.6M | $484.4M | ||
| Q3 25 | $582.5M | $616.9M | ||
| Q2 25 | $536.2M | $633.7M | ||
| Q1 25 | $552.7M | $755.7M | ||
| Q4 24 | $482.8M | $761.3M | ||
| Q3 24 | $508.4M | $754.7M | ||
| Q2 24 | $386.3M | $815.4M | ||
| Q1 24 | $663.9M | $813.8M |
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.4B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.8B | $1.5B |
| Q4 25 | 1.13× | 0.58× | ||
| Q3 25 | 1.19× | 0.45× | ||
| Q2 25 | 1.31× | 0.44× | ||
| Q1 25 | 1.27× | 0.66× | ||
| Q4 24 | 1.45× | 0.65× | ||
| Q3 24 | 1.38× | 0.66× | ||
| Q2 24 | 2.24× | 0.53× | ||
| Q1 24 | 1.37× | 0.53× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $77.7M | $23.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $73.8M | $23.2M |
| FCFマージンFCF / 売上 | 49.6% | 29.6% |
| 設備投資強度設備投資 / 売上 | 2.6% | 0.1% |
| キャッシュ転換率営業CF / 純利益 | — | — |
| 直近12ヶ月FCF直近4四半期 | $156.8M | $90.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $77.7M | $23.3M | ||
| Q3 25 | $-2.3M | $32.2M | ||
| Q2 25 | $106.4M | $33.1M | ||
| Q1 25 | $-11.2M | $2.5M | ||
| Q4 24 | $-79.9M | $34.3M | ||
| Q3 24 | $153.7M | $60.1M | ||
| Q2 24 | $47.5M | $31.0M | ||
| Q1 24 | $-62.6M | $24.8M |
| Q4 25 | $73.8M | $23.2M | ||
| Q3 25 | $-5.7M | $32.1M | ||
| Q2 25 | $103.5M | $33.0M | ||
| Q1 25 | $-14.8M | $2.4M | ||
| Q4 24 | $-81.6M | $34.0M | ||
| Q3 24 | $147.9M | $59.8M | ||
| Q2 24 | $42.9M | $30.5M | ||
| Q1 24 | $-73.4M | $24.7M |
| Q4 25 | 49.6% | 29.6% | ||
| Q3 25 | -2.5% | 41.3% | ||
| Q2 25 | 73.5% | 43.6% | ||
| Q1 25 | -6.7% | 3.0% | ||
| Q4 24 | -41.9% | 43.5% | ||
| Q3 24 | 50.3% | 75.6% | ||
| Q2 24 | 16.8% | 40.7% | ||
| Q1 24 | -24.4% | 30.6% |
| Q4 25 | 2.6% | 0.1% | ||
| Q3 25 | 1.5% | 0.2% | ||
| Q2 25 | 2.1% | 0.1% | ||
| Q1 25 | 1.6% | 0.2% | ||
| Q4 24 | 0.9% | 0.3% | ||
| Q3 24 | 2.0% | 0.3% | ||
| Q2 24 | 1.8% | 0.6% | ||
| Q1 24 | 3.6% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.34× | 18.52× | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.96× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
